Weiqing Han

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang et al. · Clinical Cancer Research · 2020 · 266 citations · Full text

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

Dan Liu, Jun Zhou, Yongsheng Wang et al. · BMC Medicine · 2022 · 73 citations · Full text

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial

Weijie Gu, Weiqing Han, Hong Luo et al. · The Lancet Oncology · 2022 · 61 citations

Hormone-sensitive Prostate Cancer, Androgen-deprivation Therapy, Urology +9

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Yuanyuan Qu, Zhongquan Sun, Weiqing Han et al. · Journal for ImmunoTherapy of Cancer · 2022 · 31 citations · Full text

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China

Yinghao Sun, Liping Xie, Tao Xu et al. · Asian journal of urology · 2019 · 28 citations · Full text